Skip to main content
Top
Published in: Current Atherosclerosis Reports 3/2011

01-06-2011

Experimental Models for the Investigation of High-Density Lipoprotein–Mediated Cholesterol Efflux

Authors: Carlos G. Santos-Gallego, Chiara Giannarelli, Juan José Badimón

Published in: Current Atherosclerosis Reports | Issue 3/2011

Login to get access

Abstract

Reduction of low-density lipoprotein cholesterol by statin therapy has only modestly decreased coronary heart disease (CHD)-associated mortality in developed countries, which has prompted the search for alternative therapeutic strategies for CHD. Epidemiologic and interventional studies have clearly established an inverse association between plasma levels of high-density lipoprotein (HDL) cholesterol and incidence of atherosclerosis. The atheroprotective benefits of HDL are not only dependent on HDL concentrations (quantity), but also on HDL function (quality). Therefore, several techniques have been recently developed to assess the different properties of HDL. Because reverse cholesterol transport (RCT) is considered a key player in the beneficial action of HDL, this review focuses on the different methods used to evaluate cholesterol efflux. Measuring the in vivo function of HDL could be of significant importance for both the clinical evaluation of an individual patient and to evaluate the effectiveness of different RCT-enhancing therapeutic approaches.
Literature
2.
go back to reference • Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670–81. Further reductions in LDL-C safely produce definite further reductions in the incidence of CVD events (acute MI, revascularization and ischemic stroke). Each 40-mg/dL (1-mM) reduction decreases CVD events by 20%. There was no evidence of any threshold within the cholesterol range studied. • Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670–81. Further reductions in LDL-C safely produce definite further reductions in the incidence of CVD events (acute MI, revascularization and ischemic stroke). Each 40-mg/dL (1-mM) reduction decreases CVD events by 20%. There was no evidence of any threshold within the cholesterol range studied.
3.
go back to reference Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–504.PubMedCrossRef Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–504.PubMedCrossRef
4.
go back to reference Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373–81.PubMedCrossRef Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373–81.PubMedCrossRef
5.
go back to reference Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–10.PubMedCrossRef Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–10.PubMedCrossRef
6.
go back to reference •• deGoma EM, Leeper NJ, Heidenreich PA. Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol 2008;51:49–55. The inverse relationship between HDL-C and coronary risk persists even among patients with LDL-C below 60 mg/dL (mean LDL-C of 48 mg/dL in this study). •• deGoma EM, Leeper NJ, Heidenreich PA. Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol 2008;51:49–55. The inverse relationship between HDL-C and coronary risk persists even among patients with LDL-C below 60 mg/dL (mean LDL-C of 48 mg/dL in this study).
7.
go back to reference •• Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med 2010;153:800–8. Statins do not alter the protective role of HDL-C, and statin treatment does not affect the inverse relationship between HDL-C level and cardiovascular risk. Low levels of HDL-C remain significantly and independently associated with increased risk despite statin treatment. The remaining risk seen in statin-treated patients may be partly explained by low HDL-C levels. •• Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med 2010;153:800–8. Statins do not alter the protective role of HDL-C, and statin treatment does not affect the inverse relationship between HDL-C level and cardiovascular risk. Low levels of HDL-C remain significantly and independently associated with increased risk despite statin treatment. The remaining risk seen in statin-treated patients may be partly explained by low HDL-C levels.
8.
go back to reference Franceschini G, Sirtori CR, Capurso 2nd A, Weisgraber KH, Mahley RW. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest. 1980;66:892–900.PubMedCrossRef Franceschini G, Sirtori CR, Capurso 2nd A, Weisgraber KH, Mahley RW. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest. 1980;66:892–900.PubMedCrossRef
9.
go back to reference Kozarsky KF, Donahee MH, Rigotti A, Iqbal SN, Edelman ER, Krieger M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature. 1997;387:414–7.PubMedCrossRef Kozarsky KF, Donahee MH, Rigotti A, Iqbal SN, Edelman ER, Krieger M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature. 1997;387:414–7.PubMedCrossRef
10.
go back to reference Zhang Y, Da Silva JR, Reilly M, Billheimer JT, Rothblat GH, Rader DJ. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest. 2005;115:2870–4.PubMedCrossRef Zhang Y, Da Silva JR, Reilly M, Billheimer JT, Rothblat GH, Rader DJ. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest. 2005;115:2870–4.PubMedCrossRef
11.
go back to reference Van Eck M, Twisk J, Hoekstra M, et al. Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver. J Biol Chem. 2003;278:23699–705.PubMedCrossRef Van Eck M, Twisk J, Hoekstra M, et al. Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver. J Biol Chem. 2003;278:23699–705.PubMedCrossRef
12.
go back to reference Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304–16.PubMedCrossRef Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304–16.PubMedCrossRef
13.
go back to reference Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356:1620–30.PubMedCrossRef Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356:1620–30.PubMedCrossRef
14.
go back to reference Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007;370:153–60.PubMedCrossRef Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007;370:153–60.PubMedCrossRef
15.
go back to reference •• Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011;364:127–35. One of the first articles demonstrating a relation between HDL function (assessed as macrophage cholesterol efflux) and atherosclerosis presence independently of HDL quantity. HDL capacity to accept cholesterol from macrophage efflux is a strong predictor of atherosclerosis in two independent populations (CIMT and angiographic CHD), independently of HDL and apoA-I concentrations. •• Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011;364:127–35. One of the first articles demonstrating a relation between HDL function (assessed as macrophage cholesterol efflux) and atherosclerosis presence independently of HDL quantity. HDL capacity to accept cholesterol from macrophage efflux is a strong predictor of atherosclerosis in two independent populations (CIMT and angiographic CHD), independently of HDL and apoA-I concentrations.
16.
go back to reference Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108:2751–6.PubMedCrossRef Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108:2751–6.PubMedCrossRef
17.
go back to reference Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res. 2006;98:1352–64.PubMedCrossRef Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res. 2006;98:1352–64.PubMedCrossRef
18.
go back to reference Santos-Gallego CG, Ibanez B, Badimon JJ. HDL-cholesterol: is it really good? Differences between apoA-I and HDL. Biochem Pharmacol. 2008;76:443–52.PubMedCrossRef Santos-Gallego CG, Ibanez B, Badimon JJ. HDL-cholesterol: is it really good? Differences between apoA-I and HDL. Biochem Pharmacol. 2008;76:443–52.PubMedCrossRef
19.
go back to reference van der Velde AE, Brufau G, Groen AK. Transintestinal cholesterol efflux. Curr Opin Lipidol. 2010;21:167–71. van der Velde AE, Brufau G, Groen AK. Transintestinal cholesterol efflux. Curr Opin Lipidol. 2010;21:167–71.
20.
go back to reference Zhang Y, McGillicuddy FC, Hinkle CC, et al. Adipocyte modulation of high-density lipoprotein cholesterol. Circulation. 2010;121:1347–55.PubMedCrossRef Zhang Y, McGillicuddy FC, Hinkle CC, et al. Adipocyte modulation of high-density lipoprotein cholesterol. Circulation. 2010;121:1347–55.PubMedCrossRef
21.
go back to reference • Smith JD. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol. 2010;30:151–5. This is a good review about the pathophysiology of dysfunctional HDL-C. HDL and apoA-I may become dysfunctional or even pro-inflammatory and thus promote atherosclerosis. ApoA-I post-translational modification can have a large impact on its function. These studies provide the basis for clinical measures of HDL modification and dysfunction, which may be useful as a treatment criterion. • Smith JD. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol. 2010;30:151–5. This is a good review about the pathophysiology of dysfunctional HDL-C. HDL and apoA-I may become dysfunctional or even pro-inflammatory and thus promote atherosclerosis. ApoA-I post-translational modification can have a large impact on its function. These studies provide the basis for clinical measures of HDL modification and dysfunction, which may be useful as a treatment criterion.
22.
go back to reference Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004;114:529–41.PubMed Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004;114:529–41.PubMed
23.
go back to reference Hoang A, Murphy AJ, Coughlan MT, et al. Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia. 2007;50:1770–9.PubMedCrossRef Hoang A, Murphy AJ, Coughlan MT, et al. Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia. 2007;50:1770–9.PubMedCrossRef
24.
go back to reference •• McGillicuddy FC, de la Llera Moya M, Hinkle CC, et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation 2009;119:1135–45. This is an elegant article demonstrating macrophage-specific RCT impairment due to inflammation. Low-dose endotoxemia decreases hepatic excretion for cholesterol, whereas high-dose endotoxemia also reduces cholesterol efflux from foam cells to HDL-C. •• McGillicuddy FC, de la Llera Moya M, Hinkle CC, et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation 2009;119:1135–45. This is an elegant article demonstrating macrophage-specific RCT impairment due to inflammation. Low-dose endotoxemia decreases hepatic excretion for cholesterol, whereas high-dose endotoxemia also reduces cholesterol efflux from foam cells to HDL-C.
25.
go back to reference •• deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol. 2008;51:2199–211. Excelent review about different approaches for evaluating HDL-C function (antiinflammatory, antioxidant, antiapoptotic, endothelial, RCT). •• deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol. 2008;51:2199–211. Excelent review about different approaches for evaluating HDL-C function (antiinflammatory, antioxidant, antiapoptotic, endothelial, RCT).
26.
go back to reference Czubayko F, Beumers B, Lammsfuss S, Lutjohann D, von Bergmann K. A simplified micro-method for quantification of fecal excretion of neutral and acidic sterols for outpatient studies in humans. J Lipid Res. 1991;32:1861–7.PubMed Czubayko F, Beumers B, Lammsfuss S, Lutjohann D, von Bergmann K. A simplified micro-method for quantification of fecal excretion of neutral and acidic sterols for outpatient studies in humans. J Lipid Res. 1991;32:1861–7.PubMed
27.
go back to reference Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 1990;85:1234–41.PubMedCrossRef Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 1990;85:1234–41.PubMedCrossRef
28.
go back to reference Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292–300.PubMedCrossRef Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292–300.PubMedCrossRef
29.
go back to reference Eriksson M, Carlson LA, Miettinen TA, Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation. 1999;100:594–8.PubMed Eriksson M, Carlson LA, Miettinen TA, Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation. 1999;100:594–8.PubMed
30.
go back to reference Groen AK, Bloks VW, Bandsma RH, Ottenhoff R, Chimini G, Kuipers F. Hepatobiliary cholesterol transport is not impaired in Abca1-null mice lacking HDL. J Clin Invest. 2001;108:843–50.PubMed Groen AK, Bloks VW, Bandsma RH, Ottenhoff R, Chimini G, Kuipers F. Hepatobiliary cholesterol transport is not impaired in Abca1-null mice lacking HDL. J Clin Invest. 2001;108:843–50.PubMed
31.
go back to reference Tchoua U, D’Souza W, Mukhamedova N, et al. The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport. Cardiovasc Res. 2008;77:732–9.PubMedCrossRef Tchoua U, D’Souza W, Mukhamedova N, et al. The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport. Cardiovasc Res. 2008;77:732–9.PubMedCrossRef
32.
go back to reference Brousseau ME, Diffenderfer MR, Millar JS, et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol. 2005;25:1057–64.PubMedCrossRef Brousseau ME, Diffenderfer MR, Millar JS, et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol. 2005;25:1057–64.PubMedCrossRef
33.
go back to reference Fielding PE, Fielding CJ, Havel RJ, Kane JP, Tun P. Cholesterol net transport, esterification, and transfer in human hyperlipidemic plasma. J Clin Invest. 1983;71:449–60.PubMedCrossRef Fielding PE, Fielding CJ, Havel RJ, Kane JP, Tun P. Cholesterol net transport, esterification, and transfer in human hyperlipidemic plasma. J Clin Invest. 1983;71:449–60.PubMedCrossRef
34.
go back to reference de la Llera Moya M, Atger V, Paul JL, et al. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. Arterioscler Thromb. 1994;14:1056–65.PubMed de la Llera Moya M, Atger V, Paul JL, et al. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. Arterioscler Thromb. 1994;14:1056–65.PubMed
35.
go back to reference Chirinos JA, Zambrano JP, Chakko S, et al. Ability of serum to decrease cellular acylCoA:cholesterol acyl transferase activity predicts cardiovascular outcomes. Circulation. 2005;112:2446–53.PubMedCrossRef Chirinos JA, Zambrano JP, Chakko S, et al. Ability of serum to decrease cellular acylCoA:cholesterol acyl transferase activity predicts cardiovascular outcomes. Circulation. 2005;112:2446–53.PubMedCrossRef
36.
go back to reference • de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 2010;30:796–801. This is a modification of the original cellular cholesterol efflux assay (explained in de la Llera Moya et al. [34]) that allows the assessment of individual molecular pathways of cholesterol efflux. • de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 2010;30:796–801. This is a modification of the original cellular cholesterol efflux assay (explained in de la Llera Moya et al. [34]) that allows the assessment of individual molecular pathways of cholesterol efflux.
37.
go back to reference van Dam MJ, de Groot E, Clee SM, et al. Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet. 2002;359:37–42.PubMedCrossRef van Dam MJ, de Groot E, Clee SM, et al. Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet. 2002;359:37–42.PubMedCrossRef
38.
go back to reference Navab M, Anantharamaiah GM, Reddy ST, et al. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation. 2004;109:3215–20.PubMedCrossRef Navab M, Anantharamaiah GM, Reddy ST, et al. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation. 2004;109:3215–20.PubMedCrossRef
39.
go back to reference Singaraja RR, Fievet C, Castro G, et al. Increased ABCA1 activity protects against atherosclerosis. J Clin Invest. 2002;110:35–42.PubMed Singaraja RR, Fievet C, Castro G, et al. Increased ABCA1 activity protects against atherosclerosis. J Clin Invest. 2002;110:35–42.PubMed
40.
go back to reference Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH, Rader DJ. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation. 2003;108:661–3.PubMedCrossRef Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH, Rader DJ. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation. 2003;108:661–3.PubMedCrossRef
41.
go back to reference Moore RE, Navab M, Millar JS, et al. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ Res. 2005;97:763–71.PubMedCrossRef Moore RE, Navab M, Millar JS, et al. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ Res. 2005;97:763–71.PubMedCrossRef
42.
go back to reference • Escola-Gil JC, Rotllan N, Julve J, Blanco-Vaca F. In vivo macrophage-specific RCT and antioxidant and antiinflammatory HDL activity measurements: New tools for predicting HDL atheroprotection. Atherosclerosis 2009;206:321–7. This is a succinct review of the different effects of genetically engineered animal models on macrophage-specific RCT and HDL-C metabolism • Escola-Gil JC, Rotllan N, Julve J, Blanco-Vaca F. In vivo macrophage-specific RCT and antioxidant and antiinflammatory HDL activity measurements: New tools for predicting HDL atheroprotection. Atherosclerosis 2009;206:321–7. This is a succinct review of the different effects of genetically engineered animal models on macrophage-specific RCT and HDL-C metabolism
43.
go back to reference Sehayek E, Hazen SL. Cholesterol absorption from the intestine is a major determinant of reverse cholesterol transport from peripheral tissue macrophages. Arterioscler Thromb Vasc Biol. 2008;28:1296–7.PubMedCrossRef Sehayek E, Hazen SL. Cholesterol absorption from the intestine is a major determinant of reverse cholesterol transport from peripheral tissue macrophages. Arterioscler Thromb Vasc Biol. 2008;28:1296–7.PubMedCrossRef
44.
go back to reference Voogt JKS, Murphy L, Hellerstein MK, Turner SM. Measurement of cholesterol efflux and global cholesterol transport rates in vivo with stable isotopes. Paper presented at: Arteriosclerosis, Thrombosis, and Vascular Biology Annual Conference; April 19–21, 2007; Chicago, IL. 2007;2. Voogt JKS, Murphy L, Hellerstein MK, Turner SM. Measurement of cholesterol efflux and global cholesterol transport rates in vivo with stable isotopes. Paper presented at: Arteriosclerosis, Thrombosis, and Vascular Biology Annual Conference; April 19–21, 2007; Chicago, IL. 2007;2.
45.
go back to reference Osono Y, Woollett LA, Marotti KR, Melchior GW, Dietschy JM. Centripetal cholesterol flux from extrahepatic organs to the liver is independent of the concentration of high density lipoprotein-cholesterol in plasma. Proc Natl Acad Sci U S A. 1996;93:4114–9.PubMedCrossRef Osono Y, Woollett LA, Marotti KR, Melchior GW, Dietschy JM. Centripetal cholesterol flux from extrahepatic organs to the liver is independent of the concentration of high density lipoprotein-cholesterol in plasma. Proc Natl Acad Sci U S A. 1996;93:4114–9.PubMedCrossRef
46.
go back to reference Jolley CD, Woollett LA, Turley SD, Dietschy JM. Centripetal cholesterol flux to the liver is dictated by events in the peripheral organs and not by the plasma high density lipoprotein or apolipoprotein A-I concentration. J Lipid Res. 1998;39:2143–9.PubMed Jolley CD, Woollett LA, Turley SD, Dietschy JM. Centripetal cholesterol flux to the liver is dictated by events in the peripheral organs and not by the plasma high density lipoprotein or apolipoprotein A-I concentration. J Lipid Res. 1998;39:2143–9.PubMed
47.
go back to reference Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet. 1977;1:965–8.PubMedCrossRef Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet. 1977;1:965–8.PubMedCrossRef
48.
go back to reference Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986;256:2835–8.PubMedCrossRef Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986;256:2835–8.PubMedCrossRef
49.
go back to reference Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA 1982;248:1465–77. Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA 1982;248:1465–77.
50.
go back to reference Lipid Research Clinics Program. JAMA 1984;252:2545–8. Lipid Research Clinics Program. JAMA 1984;252:2545–8.
51.
go back to reference Kitamura A, Iso H, Naito Y, et al. High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men. Circulation. 1994;89:2533–9.PubMed Kitamura A, Iso H, Naito Y, et al. High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men. Circulation. 1994;89:2533–9.PubMed
52.
go back to reference Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996;124(Suppl):S11–20.PubMedCrossRef Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996;124(Suppl):S11–20.PubMedCrossRef
53.
go back to reference Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol. 1997;17:107–13.PubMed Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol. 1997;17:107–13.PubMed
54.
go back to reference Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001;104:1108–13.PubMedCrossRef Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001;104:1108–13.PubMedCrossRef
55.
go back to reference Luc G, Bard JM, Ferrieres J, et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol. 2002;22:1155–61.PubMedCrossRef Luc G, Bard JM, Ferrieres J, et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol. 2002;22:1155–61.PubMedCrossRef
56.
go back to reference Badimon JJ, Santos-Gallego CG, Badimon L. Importance of HDL cholesterol in atherothrombosis: how did we get here? Where are we going? Rev Esp Cardiol. 2010;63 Suppl 2:20–35.PubMedCrossRef Badimon JJ, Santos-Gallego CG, Badimon L. Importance of HDL cholesterol in atherothrombosis: how did we get here? Where are we going? Rev Esp Cardiol. 2010;63 Suppl 2:20–35.PubMedCrossRef
Metadata
Title
Experimental Models for the Investigation of High-Density Lipoprotein–Mediated Cholesterol Efflux
Authors
Carlos G. Santos-Gallego
Chiara Giannarelli
Juan José Badimón
Publication date
01-06-2011
Publisher
Current Science Inc.
Published in
Current Atherosclerosis Reports / Issue 3/2011
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-011-0177-0

Other articles of this Issue 3/2011

Current Atherosclerosis Reports 3/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.